Glenmark Pharmaceuticals has introduced Glempa, a new range of medications featuring Empagliflozin, aimed at managing type 2 diabetes (T2DM) and heart failure in India. This launch strengthens Glenmark’s cardiometabolic portfolio, reinforcing its dedication to providing effective and affordable healthcare solutions.

Glempa includes Empagliflozin (10/25 mg) as a standalone SGLT2 inhibitor, along with two fixed-dose combinations: Glempa-L (Empagliflozin + Linagliptin) and Glempa-M (Empagliflozin + Metformin). These medications are designed to enhance glycemic control and reduce cardiovascular risks in patients with T2DM and established cardiovascular disease (CVD).

Clinical studies highlight Empagliflozin’s cardiovascular and renal benefits, with the EMPA-REG trial showing a 14% reduction in major cardiovascular events. Additional research indicates that its combination with Metformin or Linagliptin significantly lowers HbA1c levels, fasting blood sugar, and body weight.

Alok Malik, President and Head of India Formulations Business at Glenmark, emphasized the company’s commitment to innovative and accessible cardiometabolic care. By offering diverse treatment options, the Glempa range provides flexibility and effectiveness in managing diabetes and associated complications.

With rising cases of diabetes and cardiovascular diseases in India, Glenmark’s Glempa range aims to improve health outcomes by providing affordable, high-quality treatment options for millions of patients.